93591-91-4

Basic information

• Product Name: 1-Pyrrolidinecarboxylicacid,3-hydroxy-,ethylester(6CI,9CI)
• Synonyms: 1-Pyrrolidinecarboxylicacid,3-hydroxy-,ethylester(6CI,9CI);3-hydroxy-1-Pyrrolidinecarboxylic acid ethyl ester
• CAS NO: 93591-91-4
• Molecular Formula: C₇H₁₃NO₃
• Molecular Weight: 159.18302
• Product Categories: CARBOXYLICESTER
• Mol File: 93591-91-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Pyrrolidinecarboxylicacid,3-hydroxy-,ethylester(6CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinecarboxylicacid,3-hydroxy-,ethylester(6CI,9CI)(93591-91-4)
• EPA Substance Registry System: 1-Pyrrolidinecarboxylicacid,3-hydroxy-,ethylester(6CI,9CI)(93591-91-4)

Safety Data

• Hazardous Substances Data: 93591-91-4(Hazardous Substances Data)

Upstream product

• 40499-83-0 pyrrolidin-3-ol 
• 19213-72-0 ethyl 1-imidazolecarboxylate 
• 541-41-3 chloroformic acid ethyl ester 
• 775-15-5 1-benzyl-3-pyrrolidinol 
• 14891-10-2 ethyl-3-oxo-1-pyrrolidinecarboxylate 
• 64-17-5 ethanol 
• 7732-18-5 water 

Downstream Products

• 96431-51-5 3-(4-chloro-phenyl)-3-hydroxy-pyrrolidine-1-carboxylic acid ethyl ester 

Relevant articles and documents

Stereo-complementary bioreduction of saturated N-heterocyclic ketones

The asymmetric bioreduction of several saturated N-heterocyclic ketones is demonstrated in a stereo-complementary fashion using the ketoreductases READH and ChKRED20 for the production of (S)- and (R)-alcohols, respectively. The reaction accepts substrates with a five-, six- or seven-membered ring, and exhibits excellent stereoselectivity when using 2-propanol as both the ultimate reducing agent and cosolvent, achieve >99% ee in the majority of cases for both enantiomers.

Synthesis and evaluation of ligands for D2-like receptors: The role of common pharmacophoric groups

Arylcycloalkylamines, such as phenyl piperidines and piperazines and their arylalkyl substituents, constitute pharmacophoric groups exemplified in several antipsychotic agents. A review of previous reports indicates that arylalkyl substituents can improve

Pharmaceutically active compounds

Compounds of formula (I) wherein: R1 and R19 independently represent hydrogen, alkyl C1-6, alkoxy C1-6, alkylthio C1-6, halogen, hydroxyl or amino; R2 represents H or alkyl; R3 represents phenyl, a 6-membered heterocyclic aromatic ring containing one or two nitrogen atoms, or a 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O,N, and S, which phenyl or heterocyclic aromatic ring may be optionally substituted by alkyl C1-6, alkoxy C1-6, haologen, hydroxyl, alkylthio C1-6, cyano, trifluoromethyl, nitro, hydroxymethyl, amino, a group --(CH2)c NHCO2 R10, a group --(CH2)c NR5 R6, or a group --CO2 R11 ; or R3 represents hydrogen or alkyl C1-8, which alkyl group may be optionally substituted by amino or a group --NHCO2 R10 ; R4 represents hydrogen or alkyl C1-6; or R3 and R4 taken together represent a group (CH2)a Z(CH2)b ; c represents an integer 0 to 2; and pharmaceutically acceptable salts thereof, have been found to be useful as a pharmaceuticals. The compounds may especially be used in the treatment of inflammatory disorders.